The latest market report published by Credence Research, Inc. “Global Artificial Pancreas Device Systems Market
- Growth, Share, Opportunities, Competitive Analysis, and Forecast,
2016 - 2022,” the artificial pancreas device systems market was valued
at USD 59.8 Mn in 2015, and is expected to reach USD 335.5 Mn by 2022,
expanding at a CAGR of 21.7% from 2016 to 2022.
Browse the full report
Artificial Pancreas Device Systems Market - Growth, Share,
Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 at http://www.credenceresearch.com/report/artificial-pancreas-device-systems-market
Market Insights
An artificial pancreas system comprises a
continuous glucose monitor (CGM) and a continuous subcutaneous insulin
infusion pump, both of which are available in the market today, and a
controller linking the monitor and pump. It runs a highly sophisticated
algorithm to determine the appropriate amount of insulin to deliver and
the timing for that delivery, based on evaluation of real-time glucose
readings. The market segmentation of artificial pancreas device systems
market by type of devices comprises threshold suspend device system,
control-to-range (CTR) system, and control-to-target (CTT) system. The
geographical segmentation of global artificial pancreas device
systemsmarket comprises North America, Europe, Asia Pacific, Latin
America and Middle East and Africa further segmented into key countries
with highest potential in artificial pancreas device systems market.
Threshold suspended device system is
expected to account for the largest market due to early bird benefits
and swift market expansion and penetration characteristics possessed as
Medtronic, Inc. is a multinational company with operations in more than
140 countries. However, in 2018 products in CTT systems are expected to
boost the overall market growth of the artificial pancreas device and
systems market because around five companies are expected to enter the
market. North America is expected to be the largest and most potential
regional market for artificial pancreas device systems due to high
disposable income, rising prevalence of type 1 diabetes, high adoption
rate of novel technologies and supportive reimbursement policies.
Market Competition Assessment
In 2015, Medtronic, Inc. was observed as
the only player present in market with its first generation artificial
pancreas device systems MiniMed 530G. However, the key players who are
expected to enter the market during the forecast period are Johnson
& Johnson, Tendem, Insulet, JDRF, Bigfoot Biomedical and Beta
Bionics. Insulet Corp. is compiling a strategy its pump OmniPod becomes
an important part of its artificial pancreas offering in the near
future. Tandem Diabetes Care outlines its plans in the APDS market
initiating with R&D phase of its artificial pancreas system. Bigfoot
Biomedical’s goal is to create a pump-sensor union therapy that would
be much simpler than the current counterparts would. Beta Bionics has
developed the iLet Bionic Pancreas system that delivers both insulin and
glucagon and is targeted to type 1 diabetes patients; and was developed
by Dr. Ed Damiano at the Boston University. Thus, by 2019 products of
these key players are anticipated to commercially exist in the market
which would increase the market competition, new pricing strategies,
assist merger and acquisitions, and geographical expansion strategies.
Key Market Movements
- North America is expected to lead the global artificial pancreas device systems market due to high disposable income, rising prevalence of type 1 diabetes, high adoption rate of novel technologies and supportive reimbursement policies
- Projected market entry of around seven products by 2018 in global pancreas device systems market
- Artificial pancreas device systems
market is expected to achieve maturity by 2022 which would intensify the
market competition, revamp of pricing strategies, and emphasis on
geographical expansion and penetration
Download
Free Sample Request: http://www.credenceresearch.com/sample-request/57854
About
Us:
Credence
Research is a worldwide market research and counseling firm that serves driving
organizations, governments, non-legislative associations, and not-for-benefits.
We offer our customers some assistance with making enduring enhancements to
their execution and understand their most imperative objectives. Over almost a
century, we've manufactured a firm extraordinarily prepared for this
task.
Media
Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph.: 1-800-361-8290
Website: http://www.credenceresearch.com
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph.: 1-800-361-8290
Website: http://www.credenceresearch.com

No comments:
Post a Comment